Skip to content

In depth

Systemic sclerosis and exercise

What the exercise trials in systemic sclerosis found, why the largest one missed significance on its blood flow measure, and what a position paper cannot show.

The trials in this disease are small, and the gains they show in fitness are real ones. The claim that exercise changes the disease itself comes from a position paper rather than from a patient outcome. That distinction is the whole of this page.

Quick answerThe largest trial ran 12 weeks of interval training in 34 people with limited skin disease. Peak oxygen uptake rose in both exercise groups, and oxygen at the skin rose in one group only, with a large effect that missed significance. A separate review found resistance work improved strength and quality of life without recording how much.
The strongest-sounding claim in this area comes from a position paper rather than from a trial. A specialist group argues there for exercise as a disease-changing treatment in systemic sclerosis, sets out a research plan, and reports no patient outcome of its own. Its account of calming inflammation and scarring is the authors' summary of the biology, and it is not something they measured. That difference is the difference between an argument for research and a result. One says somebody ought to look, and the other says somebody looked and found something.

What the research found.

  • One trial split 34 people with limited skin systemic sclerosis three ways, with two groups doing interval training and one acting as a control. Training ran twice a week for a total of 12 weeks. Peak oxygen uptake rose in both of the exercise groups by the end of the program.

    Mitropoulos and colleagues, Arthritis Research and Therapy, 2018

  • In that trial, oxygen at the skin rose in the arm-cranking group and in neither of the others. The effect size was 0.93 and the P value was 0.59. So the result came nowhere near significance, which is what a trial of 34 people split three ways tends to produce.

    Mitropoulos and colleagues, Arthritis Research and Therapy, 2018

  • One review looked at resistance exercise in systemic sclerosis and reported the direction of three outcomes without their sizes. Muscle strength improved, physical disability fell, and quality of life improved. The group studied was about 85 percent female, and our record for that review holds no effect sizes at all.

    Mallmann and colleagues, Advances in Rheumatology, 2025

  • One specialist group wrote a position paper that argues for exercise as a disease-changing treatment in systemic sclerosis. It sets out early guidance along with a research plan for the field. It reports no patient outcome of its own, and that is the part most readers of it miss entirely.

    Pettersson and colleagues, Best Practice and Research Clinical Rheumatology, 2021

  • One trial compared silver-lined gloves against ordinary gloves in systemic sclerosis, and the two performed alike on Raynaud's burden. Both cut the Raynaud's condition score from 6.4 to 3.9. So the warmth appears to be doing the work rather than the material the gloves are made from.

    Liem and colleagues, Rheumatology, 2022

What the one real trial found

The largest exercise trial in systemic sclerosis had 34 people in it, and all of them had limited skin disease. They were split three ways, with one group doing cycling intervals, one doing arm-cranking intervals, and one acting as a control. Training ran twice a week for 12 weeks.

Peak oxygen uptake rose in both of the exercise groups, which is what you would expect from any training program. It is still worth confirming in this disease, because people with it get told to be careful about exertion. Being told to be careful is how a person stops moving.

The more interesting measure in that trial was oxygen at the skin, which estimates how much oxygen reaches it. That speaks straight to the blood vessel problem at the center of this disease, so it is the number to watch. It rose in the arm-cranking group and nowhere else.

The effect size was 0.93, which counts as large, and the P value was 0.59. So the result came nowhere near significance, with 34 people split three ways. That pairing is what a small trial looks like when it cannot answer the question it set out to ask.

Thirty-four people divided into three arms leaves very little to work with statistically. The right conclusion from it is that somebody ought to run a bigger trial of that kind. The wrong one is to quote the effect size on its own, as though the question had been settled.

The disease-changing claim, and where it comes from

You will see it said that exercise changes the disease itself in systemic sclerosis. That phrase traces to a single position paper written by a specialist group, and it does not trace to a trial. The paper states that it “recognizes the scientific basis of and advocates for education and research into exercise as a systemic and targeted disease-modifying treatment”. It then sets out early guidance and a research plan.

Read that sentence slowly, because it is a call for research and not a report of results. The paper reports no patient outcome of its own, and its account of exercise calming inflammation and scarring is the authors' summary of the underlying biology. Nothing in that document was measured in a patient.

This doesn't make the paper wrong or unimportant, and it is worth saying so plainly. It is a fair argument from mechanism, made by people who know this disease well, and arguing from mechanism is how research agendas get set. What it is not is evidence that exercise changed the course of systemic sclerosis in anybody, and that difference counts when you are deciding what to expect.

Resistance work, where the direction is known and the size isn't

One review looked at resistance exercise in this disease and reported three findings, not one with a number attached. Muscle strength improved, physical disability fell, and quality of life improved. The group studied was about 85 percent female, which is roughly the sex balance of the disease itself.

Those are the outcomes resistance training usually moves in anybody who does it. Finding them in a disease that wastes muscle and tightens skin is encouraging rather than surprising, and it is worth having. The catch is that our record for that review holds no effect sizes, no ranges, and no P values.

How large any of those gains were is therefore unrecorded on this page, and guessing at a size is not on offer. That is a limit of what has been checked for this site rather than a limit of the paper itself. Reporting the direction and saying the size is unrecorded is the honest form of it.

Put that beside the fitness results from the interval trial. Both aerobic and resistance work produced good changes in small studies, and the two have never been compared head to head. A dose has never been worked out either, and the trials that exist ran supervised programs twice a week over 12 weeks.

Raynaud's, gloves, and what the trial compared

Raynaud's is close to universal in this disease, and it is also the symptom that most people want dealt with first. One trial put silver-lined gloves against ordinary ones and measured the Raynaud's condition score in both arms. It found no difference, and both cut the score from 6.4 to 3.9.

That is a useful negative result with a positive one falling inside it, which is a rare combination. Gloves helped, and the expensive pair did not help more. So the warmth is doing the work rather than the technology, and anybody weighing a purchase gets a direct answer.

The ulcer numbers from that trial deserve stating with their limits attached to them. Three people got new ulcers wearing normal gloves against one wearing the silver-lined pair, which is an odds ratio of 3.2. The study puts the true value somewhere between 0.32 and 31.1, and a range that wide covers a real benefit and a real harm alike. So the ulcer comparison settles nothing at all.

What to do with all of this

The evidence supports exercising for fitness, strength, and function, and it does that in small trials with no dose established. It does not support the claim that exercise changes the disease itself. The source quoted most often for that claim says as much about itself, and holding both of those at once is the accurate position.

Get new breathlessness assessed. Don't put it down to being unfit. Lung involvement and high blood pressure in the lungs are what set the outlook in systemic sclerosis, which is why it is worth checking. The interval trial also recruited people with limited skin disease rather than everybody with this diagnosis, and that selection counts.

Work with somebody who knows this disease if you can find them. Skin tightening changes what you can grip and how far you can move, and hand involvement changes what equipment works for you. A general exercise program covers no part of that, so a physiotherapist who has seen systemic sclerosis before is worth more here than any protocol.

Common misconceptions.

Myth. Exercise is a disease-modifying treatment in systemic sclerosis.

Reality. That phrase comes from a position paper arguing for research into exercise as one, rather than from a trial showing that it is. The paper reports no patient outcome of its own. Its account of calming inflammation and scarring is a summary of the biology rather than a measurement, so it is an argument for studying the question. That is a different thing from an answer to it.

Myth. Exercise improves the circulation in the skin.

Reality. The trial that measured this directly is the reason to be careful about saying so. Oxygen at the skin rose in the arm-cranking group, the effect size was 0.93, and the P value was 0.59. So it missed significance in a trial of 34 people. A large effect that misses significance in a small trial is a reason to run a bigger one rather than a result to act on.

Myth. Special gloves will help my Raynaud's more than ordinary ones.

Reality. One trial in systemic sclerosis compared them and found no difference on the Raynaud's condition score. Both kinds cut it from 6.4 to 3.9, so the warmth is doing the work and the technology is not. The score improved either way, which is worth knowing before you spend anything.

Myth. The exercise research in this disease is substantial.

Reality. The largest trial had 34 people in it, and the resistance review is a written summary whose record holds no effect sizes. The document quoted most often is a position paper with no outcomes of its own. So this is a small field, and the direction of travel is encouraging while the sizes are mostly unmeasured.

Cautions specific to this condition.

  • Get new breathlessness assessed. Don't put it down to being unfit. Lung involvement and high blood pressure in the lungs are what change the outlook in this disease.
  • Ask about your heart and lungs before anything hard. The interval training trial took people with limited skin disease, not everybody with this diagnosis.
  • Keep your whole body warm, not just your hands and feet. Raynaud's answers to your core temperature as well as to local cold.
  • Report any sore or ulcer on a fingertip promptly, whatever exercise you're doing. Those get hard to heal fast.
  • Work with somebody who knows about hand and mouth involvement. Skin tightening changes what you can grip and how far you can move.
  • Expect the trials to have used supervised programs, twice a week for 12 weeks. Treat hard training on your own as untested here, not as an equivalent.

Discuss any change with the rheumatologist who manages your care. Nothing here replaces that conversation.

Questions patients ask.

What does exercise do for fitness in systemic sclerosis?

It raises it, in the one trial that measured the question properly. Thirty-four people with limited skin disease were split three ways, with one group cycling in intervals, one arm-cranking in intervals, and one acting as a control. Training ran twice a week for 12 weeks, and peak oxygen uptake rose in both exercise groups. That is a small trial, and it is also the largest of its kind here, which tells you where the field sits.

Does it improve the circulation in my skin?

That is what the interval trial tried to answer, and it could not. Oxygen at the skin rose in the arm-cranking group only, the effect size was 0.93, and the P value was 0.59. So the result came nowhere near significance with 34 people split three ways. A large effect that misses significance in a small trial is a reason to run a bigger trial rather than a finding to act on.

Is resistance training worth doing?

One review looked at resistance exercise in this disease and found strength improving, disability falling, and quality of life improving. The group studied was about 85 percent female. Our record for that review holds no effect sizes, so how large those gains were is unrecorded here. The direction is good and the size is unknown, and both of those are worth knowing before you decide how to spend your time.

Is it true that exercise modifies the disease?

That claim traces to a position paper rather than to a trial. A specialist group writes that it “recognizes the scientific basis of and advocates for education and research into exercise as a systemic and targeted disease-modifying treatment”. It then sets out early guidance and a research plan, and it reports no patient outcome of its own. Its account of the biology is a summary rather than a measurement.

What about Raynaud's, which is my worst symptom?

The most useful trial here compared two kinds of glove in systemic sclerosis. Silver-lined gloves and ordinary gloves came out level on the Raynaud's condition score. Both cut it from 6.4 to 3.9, and on ulcers three people got new ones with normal gloves against one with silver-lined. That is an odds ratio of 3.2, and the study puts the true value between 0.32 and 31.1, which is far too wide to conclude anything from.

How much should I do?

The trials used supervised programs, twice a week for 12 weeks, and the interval protocols were cycling and arm cranking. That describes what has been tested rather than what is best. Doses have never been compared in this disease, so start from what you can do now and build from there. Do it with somebody who knows the lung and heart side of this illness, because that is where the risk sits.

Is exercise safe with this diagnosis?

Nothing in these trials points to harm, and that is worth saying first. The trials were also small and selected, and the interval training study took people with limited skin disease rather than everybody. So it does not speak for everybody with this diagnosis. Lung involvement and high blood pressure in the lungs are what make this question serious, which is why new breathlessness needs assessing rather than blaming on being unfit.

References.

  1. Mitropoulos A; Gumber A; Crank H et al. The effects of upper and lower limb exercise on the microvascular reactivity in limited cutaneous systemic sclerosis patients. Arthritis Research & Therapy. 2018;20. 10.1186/s13075-018-1605-0Randomised controlled trial
  2. Mallmann A; de Moraes D; Dória L et al. Effects of interventions with resistance exercises on muscle strength, physical disability, and quality of life in systemic sclerosis patients: a systematic review with meta-analysis. Advances in Rheumatology. 2025;65. 10.1186/s42358-025-00468-1SR + MA
  3. Pettersson H; Alexanderson H; Poole JL et al. Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best practice & research. Clinical rheumatology. 2021;35:101695. 10.1016/j.berh.2021.101695Position paper
  4. Liem S; Hoekstra E; Bonte-Mineur F et al. The effect of silver fibre gloves on Raynaud’s phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial. Rheumatology. 2022;62:SI74-SI81. 10.1093/rheumatology/keac243Multicentre

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.